BRZL and AQLA

What's not to like??

BRZL up 67% today alone and news is still pending!!

AQLA up everyday for a total of almost 100%

keep tuned, more is coming.

ALQA party continues, another 30% at the moment here

TECA 1100% today

Mentioned TECA today .0002, what a great ride for this one!! hit .001

BRZL party is on

ALQA chart looking good and buys coming in

This is last month's news, but chart is setting up decent here, keep an eye on this bio-tech.

See chart below, looks good!!!

Dr. Phillip Frost made his BILLIONS investing in bio-techs I believe!!

NEW YORK, March 2, 2011 (GLOBE NEWSWIRE) -- Alliqua, Inc. (OTCBB:ALQA - News) (FWB:HL1 - News) ("Alliqua"), an advanced biomedical products company focused on the development and manufacturing of a proprietary drug delivery platform, announced the completion of a one million dollar private placement with Frost Gamma Investments Trust, headed by Miami entrepreneur Dr. Phillip Frost.

This investment will allow Alliqua to pursue the further development and commercialization for its transdermal drug delivery platform, and more specifically its pain management patch for the treatment of postherpetic neuralgia ("PHN"). PHN is associated with shingles, which is a rising medical problem in the United States and around the world, as countries continue to struggle with increasingly elderly populations. The investment will also allow Alliqua to continue development of several other proprietary products.

Dr. Phillip Frost stated, "We make this investment with enthusiasm. Alliqua has made considerable progress on the development of its PHN patch, which addresses a large and growing market. Additionally, we are impressed with the development of several other products and its IP portfolio, which has considerable market potential."

Alliqua's Chairman, David Stefansky, stated, "We are very excited to have Dr. Frost as an investor in Alliqua in light of his past accomplishments, as it demonstrates a great endorsement of our future success by one of the world's leading investors. Moreover, given Dr. Frost's knowledge and experience in the bio-medical industry, we believe that Dr. Frost's involvement in the company will be invaluable in helping us maximize shareholder value."

Matt Harriton, the CEO of Alliqua BioMedical, Inc., a wholly owned subsidiary of Alliqua, further stated, "Dr. Frost's investment is an extremely exciting affirmation of our business plan and products, especially in a field in which he has tremendous proven knowledge."

Palladium Capital Advisors, LLC acted as the Placement Agent for this transaction.

Dr. Frost, together with his affiliates, has invested more than $160 million in companies and technologies since 2006. Among his other roles, Dr. Frost is Chairman of Israel-based Teva Pharmaceuticals; Chairman of Ladenburg Thalmann Financial Services, Inc.; Chairman of OPKO Health, Inc.; Chairman of PROLOR Biotech; and, a Director of Continucare Corp.

About Alliqua Inc.

Alliqua, Inc. (OTCBB:ALQA - News) ("Alliqua"), formerly HepaLife Technologies, Inc., is an advanced biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. Through its wholly-owned subsidiary, Alliqua BioMedical, Inc., Alliqua intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform of AquaMed Technologies, Inc. ("AquaMed"), Alliqua's subsidiary.

The Alliqua, Inc. logo is available at http://www.globenews...prs/?pkgid=8820

AquaMed manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. These products use proprietary manufacturing technologies which enable AquaMed to produce what is known in the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels. AquaMed believes that it is one of two manufacturers in the world for these gels. Alliqua's third subsidiary, HepaLife Biosystems, Inc., focuses on the development of a cell-based bioartificial liver system, known as HepaMate™.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.alliqua.com and www.aquamedinc.com.

To receive future press releases via email, please visit: http://alliqua.com/i...investor-alerts

new BRZL CEO's pedigree

Info on EnCap Investments- Mr Renfro's last job:
Representing more than 250 years of experience in the energy finance and investment business
Since 1988, EnCap has been the leading provider of private equity to the independent sector of the U.S. oil & gas industry. The firm has raised 15 institutional oil and gas investment funds totaling approximately $11 billion and currently manages capital on behalf of over 200 U.S. and International investors.

EnCap professionals represent more than 250 years of experience in the energy finance and investment business and have established a reputation as an innovative, “value-added” source of private capital to the independent sector. EnCap effectively works in partnership with management teams by providing capital markets expertise, strategic direction and enhanced acquisition and exit options.

EnCap has a proven track record having successfully invested with approximately 175 upstream and midstream oil & gas companies. Throughout its 23 year history, EnCap has moved with the market to meet the changing capital needs of its clients. The combination of abundant capital resources, unparalleled experience and broad flexibility in structuring transactions uniquely positions EnCap to assist significantly in the value creation process.

BRZL update monday April 11th, our INVB tweet pick over 450% today!

We mentioned adding aggressively to our BRZL position in the 40s last week and BRZL is now in the 60s solidly today!!!

We are still very very bullish on BRZL and feel it's full potential has only been scratched here.

Aquisition news is just around the corner and BRZL is ready to blast. Join the party now.

INVB pick up over 450% today

We called INVB hovering around 25% to 50% range on twitter today and it hit over 450%
very soon after!!!

it pays to watch the tweets!

CVCP 336% GBEN 25%

We twittered CVCP at 0% today and it hit 336% in 15 minutes!!

Called GBEN as well and it hit 25% so far

we are also tracking CBIS

PRMO And BRZL

We continue to hold  PRMO and BRZL this week.

Expecting PRs at some point for both.

We still like our previous mentions LDPP, LGBS, RPPR and CLRH.